|
Market Cap (5-Jun) $61,568,592 (1,444th) |
Close (30-Jun) $0.076 |
Volume (30-Jun) 120,981 |
Shortsold (26-May) 11,577 (0.00%) (629th) |
|
52w High $0.425 |
52w Low $0.056 |
P/E - |
EPS -0.02 |
ATX released this announcement to the ASX on 17 February 2022, 8:07. The announcement is marked as price sensitive, and is 2 page(s) in length and 232.86kb in size.
You can view all announcements from ATX and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATX was 0.000% short sold according to ASIC data. It was ranked the 696th most shorted stock on the ASX. It is now ranked as the 629th most shorted stock on the ASX with 0.002% of total shares short sold as of the latest reported data (26 May 2026).
| Other Recent Announcements from ATX | |
|---|---|
| AMP945 International Nonproprietary Name Narmafotinib | 21 June 2023, 8:34 |
| Amplia AGM to be held Thursday 24 August 2023 | 19 June 2023, 17:34 |
| Key to Corporate Governance Disclosures | 31 May 2023, 8:14 |
| AMP945 Improves Survival in Human Pancreatic Cancer Model | 17 February 2022, 8:07 |
| ATX Abstract accepted for presentation at Cancer Conference | 15 February 2022, 13:41 |
| Sale of Unmarketable Parcels of Shares | 14 February 2022, 12:27 |
| Change of Director's Interest Notice - Jane Bell | 10 February 2022, 13:08 |
You must be logged in to post a reply.
Amplia Therapeutics 